QUEST DIAGNOSTICS INC — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Quest Diagnostics reported Q2 2026 revenues of $3.04B (up 10.2% YoY) with organic growth of 10.0%, and adjusted diluted EPS of $3.12 (up 19.1% YoY). The company raised full-year 2026 guidance: revenues now $11.95B–$12.05B (prior $11.78B–$11.90B); adjusted diluted EPS now $11.05–$11.25 (prior $10.63–$10.83). Growth driven by requisition volume increases of 13.1%, expansions in advanced diagnostics (Alzheimer's blood tests, cardiometabolic tests), and consumer channel growth via questhealth.com.
Why this rating
Material upside to FY guidance (≈$170M revenue midpoint increase; ≈$0.35 EPS increase) on a $20B market-cap company. Indicates sustained operational momentum and execution. Not transformational but clearly significant—demonstrates durability of organic growth model and margin expansion.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.